Roman Perez-Soler, MD, Chairman, Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine of Yeshiva University, talks about the recent advances in treatment options for non-small cell lung cancer (NSCLC).
Perez-Soler states that targeted agents represent the most dramatic changes in the treatment of NSCLC. New agents are available that target subgroups with molecular alterations in EGFR and ALK. These alterations are driver mutations in tumor cells and as a result render high response rates.
Despite the initial response to a medication most tumors will eventually develop resistance. The next step for research is to understand how these tumors develop these resistance mechanisms.
A phase III study exploring the MET inhibitor onartuzumab as a treatment for patients with NSCLC is being stopped, following an interim analysis that suggested a lack of clinically meaningful efficacy.